Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Combined Serum (1,3)-β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection of <i>Pneumocystis jirovecii</i> Pneumonia: An Observational Retrospective Study.

Open forum infectious diseases·2026

Same author

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Blood advances·2025

Same author

Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).

The Journal of antimicrobial chemotherapy·2025

Same author

Short- and long-term mortality in critically ill patients with solid cancer. The Vall d'Hebron Intensive Care Unit-Vall d'Hebron Institute of Oncology Cohort: a retrospective study.

Medicina intensiva·2025

Same author

Corrigendum to "Safety and effectiveness of isavuconazole in real-life non-neu tropenic patients" [International Journal of Infectious Diseases 144 (2024) 107070].

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024

Same author

<i>Pseudomonas aeruginosa</i> Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy.

Microorganisms·2024

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

[Combination therapy for invasive aspergillosis].

Isabel Ruiz-Camps¹

¹Servicio de Enfermedades Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España. iruiz@vhebron.net

Enfermedades Infecciosas Y Microbiologia Clinica

|March 23, 2011

Summary

Invasive aspergillosis is increasing, with high mortality. Combination antifungal therapy, particularly echinocandins with voriconazole or liposomal amphotericin B, shows potential for severe cases, though evidence is limited.

Related Experiment Videos

Last Updated: Jun 3, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Area of Science:

Medical Mycology
Infectious Diseases
Pharmacology

Background:

Invasive fungal infections, especially invasive aspergillosis, are rising globally.
High mortality rates (40-80%) persist despite new antifungal drugs.
Combination therapy is explored to improve outcomes.

Purpose of the Study:

To review the evidence for combination antifungal therapy in invasive aspergillosis.
To identify potentially synergistic combinations for severe or refractory cases.
To assess the current recommendations for combination therapy.

Main Methods:

Review of experimental models, in vitro data, and clinical studies (observational, small patient cohorts).
Analysis of studies including first-line and rescue therapy patients.
Evaluation of data on various combination regimens.

Main Results:

No definitive evidence shows combination therapy significantly outperforms monotherapy.
Combination therapy may be beneficial in severe invasive aspergillosis, including CNS or extensive pulmonary involvement.
Echinocandin (e.g., micafungin) combined with voriconazole or liposomal amphotericin B suggests synergy.

Conclusions:

Combination therapy is not proven superior to monotherapy but is considered for severe invasive aspergillosis.
Echinocandin-based combinations show promise, supported by limited clinical trial data.
Despite low evidence grade, these combinations are recommended by scientific societies for specific scenarios.